



501-3292 Production Way, Burnaby, B.C., V5A 4R4

Phone: (604) 551-7831 Fax: 604-676-2767

[info@cannabixtechnologies.com](mailto:info@cannabixtechnologies.com)

[cannabixtechnologies.com](http://cannabixtechnologies.com)

## Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology

Vancouver, British Columbia, January 9, 2025 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report that it has made significant updates to its Cannabix Marijuana Breathalyzer (“CMB”) technology to meet suggested emerging regulatory requirements in preparation for marketing. Cannabix engineers have incorporated several new features to the Company’s Breath Collection Unit (“BCU”) – a critical hardware tool used for portable collection of delta-9 THC in breath (images below). These developments come as the need for marijuana breath detection gains intensity in the United States and globally.



Cannabix Breath Collection Unit (“BCU”) with Breath Cartridge technology.

A recently published New York Times article, “*As Marijuana Use Grows, Effect on Road Safety Remains a Blind Spot*” (January 2025) highlights U.S. federal research into road safety and cannabis use, and the lack of tools to detect cannabis-impaired driving (1). Furthermore, the article discusses the limitations of existing testing methods for delta-9 THC and the increasing number of Americans consuming cannabis. The article references a 2019 survey by the *AAA Foundation for Traffic Safety* where an estimated 14.8 million drivers (in the U.S) reported getting behind the wheel within one hour after using marijuana, and 70% of Americans thinking it’s unlikely a driver will get caught by police for driving while high on marijuana (2). Cannabix’s

marijuana breathalyzer technology is focused on “recent use” detection of delta-9 THC as opposed to widely used urine, blood and saliva methods (that can detect delta-9 THC many hours, days, or even weeks after consumption) (3).

Rav Mlait, CEO of Cannabix stated, “Cannabix is at the forefront of marijuana breathalyzer technology, and we anticipate that 2025 will hold significant milestones as the Company has matured its technology, partnerships and business opportunities. In the U.S., cannabis legalization has grown to 39 states for medical use and 24 states legalized for recreational use. This represents a major growth opportunity for Cannabix in the drug testing segment.”



New Cannabix Breath Collection Unit (“BCU”) with Breath Cartridge technology.

### Highlights:

- Cannabix provides updated images of its Breath Collection Unit (“BCU”) and *Breath Cartridge* technology with several new features to the Company’s marijuana breathalyzer technology to meet industry and suggested emerging regulatory requirements.
- Major updates and improvements for the BCU include a smaller, lightweight, more ergonomic design and new removable, long-lasting, rechargeable Li-ion battery, allowing for easy battery replacement.
- The sample collection cartridge has been modified to be able to collect a single sample or dual sample consistent with federally regulated programs that require a simultaneous A & B sample collection. Furthermore, a new ambient air collection through a second cartridge is now available.
- New “on demand” periodic quality assurance check, a new startup self-check feature, and streamlined user interface.
- Cannabix is quickly advancing its marijuana breathalyzer technology, with key validation work well underway in the United States.

### References:

(1) <https://www.nytimes.com/2025/01/01/us/marijuana-driving-impairment.html>

(2) <https://newsroom.aaa.com/2019/06/americans-dont-think-theyll-get-arrested-for-driving-high/>

(3) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. *Cannabis and Cannabinoid Res.*; 99-104.

## **About Cannabix Technologies Inc.**

Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is developing delta-9 THC and alcohol screening devices. Delta-9 THC is the primary psychoactive ingredient in cannabis. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of *its Breath Logix Series of breath alcohol detection devices* for employers and a range of other settings.

We seek Safe Harbor.

*On behalf of the Board of Directors*

“Rav Mlait”

CEO

Cannabix Technologies Inc.

For further information, contact the Company at [info@cannabixtechnologies.com](mailto:info@cannabixtechnologies.com)

### ***Cautionary Statement Regarding Forward-Looking Statements***

*This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: the achievement of any or all of the goals and aims of partnerships as described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with existing and new partners; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are not limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that partners may not complete all or any of the milestones as contemplated strategic partnership agreements; that the CSE may not approve the issuance of the securities; that the Company's development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any "patent pending" or "provisional patents" technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.*

*The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.*